Stabilized formulations containing Anti-CD20 x Anti-CD3 bispecific antibodies
TW202637215APending Publication Date: 2026-09-16REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW115101780
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-10
- Filing Date
- 2020-12-08
- Publication Date
- 2026-09-16
Abstract
The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human CD20 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
Need to check novelty before this filing date? Find Prior Art